0.5792

24.02% -0.1764

Citius Pharmaceuticals Inc (CTXR)

Overview News Price History Option Chain Financials Why CTXR Down? Discussions Forecast Stock Split

Citius Pharmaceuticals Inc stock is traded at $0.5792, with a volume of 2.04M. It is down -24.02% in the last 24 hours and up +15.79% over the past month. Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Previous Close:

$0.7556

Open:

$0.622

24h Volume:

2.04M

Relative Volume:

3.58

Market Cap:

$15.91M

Revenue:

$5.61M

Net Income/Loss:

$-55.45M

P/E Ratio:

-0.2253

EPS:

-2.5703

Net Cash Flow:

$-42.35M

1W Performance:

-15.20%

1M Performance:

+15.79%

6M Performance:

-22.58%

1Y Performance:

-56.83%

1-Day Range:

$0.5486

$0.6299

1-Week Range:

$0.5486

$0.79

52-Week Range:

$0.4687

$2.19

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name

Citius Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(908) 967-6676

Address

11 COMMERCE DRIVE, CRANFORD, NJ

Employee

Twitter

Next Earnings Date

2026-08-18

Latest SEC Filings

CTXR's Discussions on Twitter

Compare CTXR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTXR Citius Pharmaceuticals Inc	0.5796	20.74M	5.61M	-55.45M	-42.35M	-2.5703
VRTX Vertex Pharmaceuticals Inc	515.31	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.34	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.59	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.30	39.31B	5.76B	514.49M	1.10B	4.4813

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Upgrade	D. Boral Capital	Hold → Buy
Nov-30-21	Initiated	Maxim Group	Buy

Citius Pharmaceuticals Inc Stock (CTXR) Latest News

Aug 16, 2026

Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - kalkinemedia.com

Aug 16, 2026

Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus

Aug 16, 2026

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

Aug 16, 2026

Aug 14, 2026

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart

Aug 14, 2026

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - intellectia.ai

Aug 14, 2026

CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView

Aug 14, 2026

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Aug 14, 2026

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Aug 14, 2026

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan

Aug 14, 2026

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Aug 13, 2026

Aug 12, 2026

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Aug 12, 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Aug 12, 2026

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Aug 12, 2026

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Aug 12, 2026

Citius Oncology appoints Jonathan Peri to board of directors - Investing.com

Aug 12, 2026

Aug 11, 2026